hVIVO, part of Open Orphan plc, was established in 1989 as a spin out from Queen Mary University, London, and is a clinical development services business pioneering human disease models based upon viral challenge. Using human challenge studies to establish early proof-of-concept, hVIVO's clinical trial platform can accelerate drug and vaccine development in respiratory and infectious diseases, hVIVO has leveraged its insights in established human disease challenge models in influenza (“Flu”), respiratory syncytial virus (“RSV”) and human rhinovirus (“HRV”) to expand the use of viral challenge in additional respiratory indications including asthma, chronic obstructive pulmonary disease (“COPD”) and cough and in special populations.

hVIVO was acquired by Open Orphan PLC in January 2020 and in now listed on the London AIM as ORPH.